RT Journal Article
SR Electronic
T1 Evolving Epidemiology and Effect of Non-pharmaceutical Interventions on the Epidemic of Coronavirus Disease 2019 in Shenzhen, China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.09.20084202
DO 10.1101/2020.05.09.20084202
A1 Huang, Suli
A1 Zhang, Zhen
A1 Wu, Yongsheng
A1 Mei, Shujiang
A1 Li, Yuan
A1 Xie, Xu
A1 Liu, Xiaojian
A1 Tang, Xiujuan
A1 Kong, Dongfeng
A1 Wu, Xiaoliang
A1 Wu, Yu
A1 Wei, Lan
A1 Lv, Ziquan
A1 Yu, Shuyuan
A1 Wen, Ying
A1 Zhou, Guohong
A1 Chen, Tianmu
A1 Feng, Tiejian
A1 Zou, Xuan
YR 2020
UL http://medrxiv.org/content/early/2020/05/13/2020.05.09.20084202.abstract
AB Previous studies have demonstrated the characteristics of patients with 2019 novel coronavirus disease (COVID-19). However, the effect of non-pharmaceutical interventions on the epidemic in Shenzhen, China remains unknown. Individual data of 417 cases were extracted from the epidemiological investigations and the National Infectious Disease Information System between January 1, 2020 and February 29, 2020. On the basis of important interventions, the epidemic was divided into four periods (January 1-15, January 16-22, January 23-February 5 and after February 6). We used a susceptible-exposed-infectious-asymptomatic-recovered model to evaluate the effect of interventions. Results suggested that about 53.7% were imported from Wuhan. The median age was 47 years and 52.8% were women. Severity risk increased with age and associated with male and co-existing disorders. The attack rate peaked in the third period and drastically decreased afterwards across sex, age groups and geographic regions. Children younger than 5 years showed a higher attack rate than those aged of 6~19. The effective reproductive number decreased from 1.44 to 0.05 after the highest level emergency response since January 23. Overall, the non-pharmaceutical interventions have effectively mitigated the COVID-19 outbreak in Shenzhen, China. These findings may facilitate the introduction of public health policies in other countries and regions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementOpen Fund of Shenzhen Bay laboratory(SZBL202002271004) SanMing Projiect of Medicine in Shenzhen (SZSM201811070).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe general information of COVID-19 cases were extracted from the field epidemiological survey reports and the National Infectious Disease Information System between January 1, 2020 and February 29, 2020, including age, sex, residential district, co-existing disorders, illness severity, source of infection, date of illness onset, hospitalization, and laboratory confirmation in bio-samples.